<< Вернуться к списку статей журнала

Том 10 №2 2008 год - Нефрология и диализ

Низкомолекулярный декстран железа и сахарат железа обладают сравнимыми параметрами безопасности при хронических заболеваниях почек

Ауэрбах М. Талиб К.Ал.

Аннотация: Тяжелые побочные реакции, встречавшиеся при применении декстрана железа, были обусловлены препаратами с высокой молекулярной массой. Суждения о том, что сахарат и глюконат железа более безопасны, чем декстран железа, преждевременны. Проанализированы опубликованные сравнения данных о безопасности доступных препаратов парентерального железа. Встречаются неоптимальные схемы применения препаратов железа у пациентов на додиализной стадии хронических заболеваний почек. Мы рекомендуем инфузию общей дозы низкомолекулярного декстрана железа как метод выбора для восполнения железа. Kidney International (2008) 73, 528-530.

Для цитирования: Ауэрбах М., Талиб К.Ал. Низкомолекулярный декстран железа и сахарат железа обладают сравнимыми параметрами безопасности при хронических заболеваниях почек. Нефрология и диализ. 2008. 10(2):159-165. doi:

Весь текст

Список литературы:

1. Feldman H.I., Joffe M., Robinson B. et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632.
2. Kalanter-Zadeh K., Regidor D.L., McAllister C.J. et al. Time dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.
3. Blaustein D.A., Schwenk M.H., Chattopadhyay J., Avram M.M. Recent experience with high-dose intravenous iron administration. Kidney Int 2006; 70: S26-S29.
4. Vikrant S. Optimum dosage regimen for iron sucrose. Kidney Int 2007; 72: 225.
5. Chandler G., Harchowal J., Macdougall I.C. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: 988-991.
6. Auerbach M., Witt D., Toler W. et al. Clinical use of the total dose infusion of iron dextran. J Lab Clin Med 1988; 111: 566-570.
7. Auerbach M., Ballard H., Glaspy J. Clinical update: intravenous iron for anemia. Lancet 2007; 369: 1502-1504.
8. Case G. Maintaining iron balance with total-dose infusion of iron dextran. ANNA J 1998; 25: 65-68.
9. Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant; 21: 378-382.
10. Silverstein S.B., Rodger G.M. Parenteral iron therapy options. Am J Hematol; 76: 74-78.
11. Mamula P., Piccoli D.A., Peck S.N. et al. dose intravenous infusion of iron dextran for irondeficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr; 34: 286-290.
12. Coyne D.W., Adkinson F.N. Jr., Nissenson A.R. et al. ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextransensitive and dextran-tolerant patients. Kidney Int; 63: 217-224.
13. McCarthy J.T., Regnier C.E., Leobertmann C.L., Bergstralh E.J. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran: a comparison of two products. Am J Nephrol; 20: 455-462.
14. Fletes R., Lazarus J.M., Gage J., Chertow J.M. Suspected iron dextran related adverse events in hemodialysis patients. Am J Kidney Dis; 37: 743-749.
15. Auerbach M., Rodgers G.M. Intravenous iron. N Engl J Med; 357: 93-94.
16. Auerbach M., Winchester J., Wahab A. et al. randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis; 31: 81-86.
17. Auerbach M., Ballard H., Trout J.R. et al. iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label randomized trial. J Clin Oncol; 22: 1301-1307.
18. Auerbach M., Chaudhry M., Goldman H., Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med; 131: 257-260.
19. Moniem K.A., Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients: a comparison of preparations. Transfusion Altern Transfusion Med 2007; 9: 37-42.
20. Critchley J., Dundar Y. Adverse events associated with intravenous iron infusion (low-molecularweight iron dextran and iron sucrose): a systematic review. Transfusion Altern Transfusion Med 2007; 9: 8-36.
21. Sav T., Tokgoz B., Sipahioglu M.H. Is there a difference between allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007; 29: 423-426.
22. Zager R.A., Johnson A.C., Hanson S.Y., Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103.
23. Pai A.B., Boyd A.V., McQuade C.R. et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007; 27: 343-350.
24. Agarwal R., Vasavada N., Sachs N.G., Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289.
25. Zager R.A., Johnson A.C., Hanson S.W. Parenteral iron exacerbates experimental sepsis. Kidney Int 2004; 65: 2108-2112.
26. Zager R.A., Johnson A.C., Hanson S.W., Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF alpha release. Am J Physiol Renal Physiol 2005; 288: F295-F297.
27. Agarwal R., Rizkala A.R., Kaskas M.O. et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int; 72: 638-642.